Personalised Postoperative Radiochemotherapy in Patients With Head and Neck Cancer
Personalised Postoperative Radiochemotherapy in Patients With Head and Neck Cancer and Development of a Multi-parametric Decision Support System for Personalised Medicine in Radiation Oncology
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Baden-Württemberg
-
Tübingen, Baden-Württemberg, Germany, 72076
- University Hospital Tübingen, Department of Radiation Oncology
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- locally-advanced HNSCC (Oro- and Hypopharynx) stage III and IV without distant metastases
- no contraindications for PET/MRI
- no contraindications for radiochemotherapy
- informed consent
- ECOG PS 0/2
Exclusion Criteria:
- Secondary malignancies that might influence outcome within 2 years after radiochemotherapy of the HNSCC
- previous PET/CT
- induction therapy
- pregnancy or breastfeeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Integration of PET/MRI in radiotherapy
Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
|
Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
locoregional progression free survival
Time Frame: 2 years after primary diagnosis
|
15% improvement in loco-regional PFS at 2 years through integrtion of pre-operative PET/MR imaging into RT treatment planning
|
2 years after primary diagnosis
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Disease free survival
Time Frame: 2 years after primary diagnosis
|
2 years after primary diagnosis
|
|
Overall survival
Time Frame: 2 years after primary diagnosis
|
2 years after primary diagnosis
|
|
Development of a multi-parametric decision support system
Time Frame: after termination of recruitment and follow up up to 5 years
|
after termination of recruitment and follow up up to 5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Daniel Zips, MD, Prof, University Hospital Tuebingen, Department of Radiation Oncology, Tuebingen, Germany
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ZPM_Demonstrator_HNC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.